Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Unresectable locally advanced and/or metastatic soft-ti 2019-10-16
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended

2023-507148-35-00 Chemotherapy-induced Thrombocytopenia in Adult Subjects 2019-10-03
Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced Ended

2023-506657-38-00 Biliary Tract Carcinoma 2019-10-02
The MiBlock study Ended

2024-515165-34-00 Chronic migraine 2019-10-01
Corticosteroid in acute urticaria in emergency department Ended

2024-515308-38-00 Adults patients with isolated acute urticaria presentin 2019-09-21
Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended

2023-505614-17-00 Participants with advanced or recurrent endometrial car 2019-09-20
A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICKHCM (MY… Ended

2022-502858-14-00 Hypertrophic cardiomyopathy 2019-09-05
Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended

2023-503956-29-00 Microsatellite Instability High (MSI-H) or Mismatch Rep 2019-08-26
Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended

2022-500785-10-00 Metastatic Castration-Resistant Prostate Cancer 2019-08-23
The Late Presenter Treatment Optimisation Study (LAPTOP) Ended

2023-505167-36-00 Patients who present late on during their acquisition o 2019-08-05
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Primary myelofibrosis, post-polycythemia vera myelofibr 2019-08-05
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension Ended

2022-502380-37-00 Open-Angle Glaucoma 2019-08-02
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Ended

2023-504928-26-00 Chronic Migraine 2019-07-19
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with lo… Ended

2023-509053-32-00 Locoregional Hepatocellular Carcinoma (HCC) 2019-07-17
Comparative multicenter randomized study of aflibercept versus placebo in macular telangiectasia type 1 Ended

2024-511885-35-00 macular telangiectasia type 1 2019-07-03
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended

2022-501439-18-00 NSCLC with squamous or nonsquamous histology 2019-06-26
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended

2023-508449-41-00 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) 2019-06-26
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended

2023-509774-40-00 Stage IV lung cancer condition 2019-06-25
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metas… Ended

2023-505009-17-00 Triple-negative Breast Cancer 2019-06-21
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome … Ended

2024-517309-95-00 -Peripheral neuropathy clinically defined: *Pure sensit 2019-06-19
Phase 3 study of SBRT ± pembrolizumab for participants with unresectable Stage I or II NSCLC Ended

2022-500413-11-00 Unresected Stage I or II Non-Small Cell Lung Cancer (NS 2019-06-17
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended

2023-509848-10-00 Multiple myeloma (MM) with at least 2 prior therapies i 2019-06-12
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eli… Ended

2022-501970-20-01 Cis-eligible Muscle-invasive bladder cancer. 2019-06-07
A research study in children with low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day Ended

2023-506829-11-00 Growth Hormone Deficiency in children 2019-05-29